Bolt Financial Statements From 2010 to 2025
| BOLT Stock | USD 0.33 0.01 3.13% |
Check Bolt Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bolt Biotherapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Bolt financial statements analysis is a perfect complement when working with Bolt Biotherapeutics Valuation or Volatility modules.
Check out the analysis of Bolt Biotherapeutics Correlation against competitors. Bolt Biotherapeutics Company Current Valuation Analysis
Bolt Biotherapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Bolt Biotherapeutics Current Valuation | (1.49 M) |
Most of Bolt Biotherapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bolt Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Bolt Biotherapeutics has a Current Valuation of (1.49 Million). This is 100.01% lower than that of the Biotechnology sector and 100.03% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.01% higher than that of the company.
Bolt Biotherapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bolt Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Bolt Biotherapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bolt Biotherapeutics competition to find correlations between indicators driving Bolt Biotherapeutics's intrinsic value. More Info.Bolt Biotherapeutics is rated fifth in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Bolt Biotherapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.About Bolt Biotherapeutics Financial Statements
Bolt Biotherapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Bolt Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Bolt Biotherapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Bolt Biotherapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California. Bolt Biotherapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 91 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Bolt Stock Analysis
When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.